BenzingaSeptember 15, 2026 at 5:52 AM NYLast Month
Raymond James Downgrades Ascendis Pharma to Outperform, Maintains Price Target to $287
Raymond James analyst Martin Auster downgrades Ascendis Pharma (NASDAQ:ASND) from Strong Buy to Outperform and maintains the price target from $287 to $287.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
